Investigational drug · Phase 3
Pelabresib
Also called: DAK539, CPI-0610
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
9
Any phase or sponsor naming "Pelabresib"
First trial start
2014
Jul 16, 2014
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pelabresib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
- Primary Myelofibrosis
- Primary Myelofibrosis (PMF)
- Post-polycythemia Vera Myelofibrosis (PPV-MF)
- Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Hematologic Malignancy
- Solid Tumor
- Advanced Malignancies
Approved drugs for the same conditions: Myelofibrosis · Oncology · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Pelabresib" as an intervention, largest first.
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07357727 · 460 participants (planned) · Start May 27, 2026 · Primary completion May 17, 2028
Drug: Pelabresib; Ruxolitinib and 1 more · For: Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Sites: Denver, Colorado; New Haven, Connecticut; Fort Myers, Florida · 174 sites in all
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04603495 · 430 participants · Start Apr 9, 2021 · Primary completion Aug 23, 2023
Drug: Pelabresib; Ruxolitinib and 1 more · For: Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis and 1 more
Sites: Birmingham, Alabama; Chandler, Arizona; La Jolla, California · 156 sites in all
Constellation PharmaceuticalsIndustry
NCT02158858 · 336 participants · Start Jul 16, 2014 · Primary completion Jan 9, 2025
Drug: Pelabresib; Ruxolitinib · For: Myelofibrosis; Leukemia, Myelocytic, Acute; Myelodysplastic/Myeloproliferative Neoplasm and 11 more
Sites: Phoenix, Arizona; Los Angeles, California; Jacksonville, Florida · 48 sites in all
- An Extension Study for Patients Previously Enrolled in Studies With PelabresibPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06401356 · 50 participants (planned) · Start Aug 13, 2024 · Primary completion Dec 31, 2029
Drug: Pelabresib; Ruxolitinib · For: Hematologic Malignancy; Solid Tumor; Advanced Malignancies
Sites: Los Angeles, California; Jacksonville, Florida; Chicago, Illinois · 15 sites in all
Constellation PharmaceuticalsIndustry
NCT05391022 · 35 participants · Start Jul 20, 2021 · Primary completion Mar 8, 2023
Drug: Pelabresib · For: Advanced Malignancies; Solid Tumor; Hematological Malignancy
Sites: Canton, Ohio; Gettysburg, Pennsylvania; West Valley City, Utah · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07783503 · 30 participants (planned) · Start Sep 2, 2026 · Primary completion Nov 13, 2026
Drug: Pelabresib; Phenytoin and 1 more · For: Healthy Participants
Sites: Nottingham, United Kingdom
Novartis PharmaceuticalsNovartis (NVS)
NCT07422610 · 24 participants (planned) · Start May 19, 2026 · Primary completion Jun 28, 2028
Drug: pelabresib · For: Advanced Malignancies and Hepatic Impairment
Sites: Bordeaux, France; Saint-Herblain, France; Milan, Italy · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07340190 · 24 participants (planned) · Start Jun 12, 2026 · Primary completion Mar 9, 2028
Drug: pelabresib; repaglinide and 3 more · For: Advanced Malignancies
Sites: Bordeaux, France; Candiolo, Italy; Pozuelo de Alarcón, Spain · 6 sites in all
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07340138 · 3 participants · Start Apr 15, 2026 · Primary completion Jul 23, 2026
Drug: Pelabresib; Ruxolitinib · For: Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (Post-PV MF); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sites: Kamogawa, Japan; Sapporo, Japan; Chūō, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
Tan S, Li Y, Cao Y, et al. · Ann Med 2026
- New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
Gangat N, Guglielmelli P, Vannucchi AM, et al. · Am J Hematol 2026
- Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy Versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients.
Zhang Y, Zhou H, Zhuang J, et al. · Clin Lymphoma Myeloma Leuk 2026
- Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML.
Statkiewicz M, Rumienczyk I, Pakulska U, et al. · Cells 2026
- Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting.
Zhang T, Jiang H, Liu D · Exp Hematol Oncol 2026
- The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis.
Bellia M, Deambrogi C, Mahmoud AM, et al. · Expert Opin Investig Drugs 2026
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
- GB2064Phase 21 trial
Galecto Biotech AB · Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.